Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans

Mehta, Nehal N.; McGillicuddy, Fiona C.; Anderson, Paul D.; Hinkle, Christine C.; Shah, Rachana; Pruscino, Leticia; Tabita-Martinez, Jennifer; Sellers, Kim F.; Rickels, Michael R.; Reilly, Muredach P.
January 2010
Diabetes;Jan2010, Vol. 59 Issue 1, p172
Academic Journal
OBJECTIVE--An emerging model of metabolic syndrome and type 2 diabetes is of adipose dysfunction with leukocyte recruitment into adipose leading to chronic inflammation and insulin resistance OR). This study sought to explore potential mechanisms of inflammatory-induced IR in humans with a focus on adipose tissue. RESEARCH DESIGN AND METHODS--We performed a 60-h endotoxemia protocol (3 ng/kg intravenous bolus) in healthy adults (n = 20, 50% male, 80% Caucasian, aged 27.3 ± 4.8 years). Before and after endotoxin, whole-blood sampling, subcutaneous adipose biopsies, and frequently sampled intravenous glucose tolerance (FSIGT) testing were performed. The primary outcome was the FSIGT insulin sensitivity index (Si). Secondary measures included inflammatory and metabolic markers and whole-blood and adipose mRNA and protein expression. RESULTS--Endotoxemia induced systemic IR as demonstrated by a 35% decrease in Si (3.17 ± 1.66 to 2.06 ± 0.73 x 10-4 [µU ⋅ ml-1 ⋅ min-1], P < 0.005), while there was no effect on pancreatic β-cell function. In adipose, endotoxemia suppressed insulin receptor substrate-1 and markedly induced suppressor of cytokine signaling proteins (1 and 3) coincident with local activation of innate (interleukin-6, tumor necrosis factor) and adaptive (monocyte chemoattractant protein-1 and CXCL10 chemokines) inflammation. These changes are known to attenuate insulin receptor signaling in model systems. CONCLUSIONS--We demonstrate, for the first time in humans, that acute inflammation induces systemic IR following modulation of specific adipose inflammatory and insulin signaling pathways. It also provides a rationale for focused mechanistic studies and a model for human proof-of-concept trials of novel therapeutics targeting adipose inflammation in IR and related consequences in humans. Diabetes 59:172-181, 2010


Related Articles

  • Inflammation: The Root of Our Chronic Diseases. Campbell, Andrew W. // Alternative Therapies in Health & Medicine;Nov/Dec2015, Vol. 21 Issue 6, p8 

    The author offers observation on inflammation as the root cause of chronic diseases. Topics addressed include the chronic health problems caused by inflammation which include metabolic syndrome, type 2 diabetes and cancer, neutrophils as the most common type of leukocytes, and significant role...

  • Beacon. Collier, Greg R.; McMillan, Janine S.; Windmill, Kelly; Walder, Ken; Tenne-Brown, Janette; de Silva, Andrea; Trevaskis, James; Jones, Sharon; Morton, Gregory J.; Lee, Scott; Augert, Guy; Civitarese, Anthony; Zimmet, Paul Z. // Diabetes;Nov2000, Vol. 49 Issue 11, p1766 

    Presents the findings of a study which used differential display polymerase chain reaction to screen mRNA isolated from the hypothalamus of lean and obese Psammomys obesus, a polygenic animal model ideal for the study of obesity and type 2 diabetes. Role of the hypothalamus in the control of...

  • Differential Expression of Novel Adiponectin Receptor-1 Transcripts in Skeletal Muscle of Subjects With Normal Glucose Tolerance and Type 2 Diabetes. Ashwal, Reut; Hemi, Rina; Tirosh, Amir; Gordin, Reut; Yissachar, Eleanor; Cohen-Dayag, Anat; Rosenberg, Avi; Karasik, Avraham; Blüher, Matthias; Kanety, Hannah // Diabetes;Mar2011, Vol. 60 Issue 3, p936 

    OBJECTIVE--Adiponectin receptor-1 (AdipoR1) expression in skeletal muscle has been suggested to play an important role in insulin resistance and diabetes. We aimed at evaluating the presence of novel AdiopR1 splice variants in human muscle and their regulation under physiological and...

  • Nutritional correlates and dynamics of diabetes in the Nile rat (Arvicanthis niloticus): a novel model for diet-induced type 2 diabetes and the metabolic syndrome. Chaabo, Fadi; Pronczuk, Andrzej; Maslova, Ekaterina; Hayes, K. C. // Nutrition & Metabolism;2010, Vol. 7, p29 

    Background: The prevalence of Metabolic Syndrome and related chronic diseases, among them non-insulindependent (type 2) diabetes mellitus, are on the rise in the United States and throughout the world. Animal models that respond to environmental stressors, such as diet, are useful for...

  • Testosterone Replacement in Diabetes and the Metabolic Syndrome.  // OB/GYN Clinical Alert;Jun2011 Clinical Brief, p12 

    The article presents a study which determines the effects of testosterone (TST) two percent gel when applied in hypogonadal men with type 2 diabetes (DM2) or metabolic syndrome (MBS) who underwent treatment for one year.

  • Testosterone Replacement in Diabetes and the Metabolic Syndrome. Kuritzky, Louis // Neurology Alert;Jun2011 Clinical Brief, p12 

    The article presents a study conducted by a team led by T. H. Jones and published in the "Diabetes Journal" that explored testosterone (TST) replacement in type 2 diabetes (DM2) and metabolic syndrome (MBS).

  • Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Sridhar, G. R.; Nirmala, G.; Apparao, Allam; Madhavi, A. S.; Sreelatha, S.; Rani, J. Sudha; Vijayalakshmi, P. // Lipids in Health & Disease;2005, Vol. 4, p18 

    Background: Butyrylcholinesterase is an enzyme that may serve as a marker of metabolic syndrome. We (a) measured its level in persons with diabetes mellitus, (b) constructed a family tree of the enzyme using nucleotide sequences downloaded from NCBI. Butyrylcholinesterase was estimated...

  • Metabolic Syndrome in Type 2 Diabetes Mellitus in Isfahan, Iran Prevalence and Risk Factors. Mohsen Janghorbani; Masoud Amini // Metabolic Syndrome & Related Disorders;Sep2007, Vol. 5 Issue 3, p243 

    Background Our goal was to estimate the prevalence and risk factors of metabolic syndrome (MetSyn) in people with type 2 diabetes mellitus (T2DM) using routinely collected data from a clinical information system at Isfahan Endocrinology and Metabolism Research Centre, Iran.Methods Consecutive...

  • Testosterone Replacement in Diabetes and the Metabolic Syndrome. Jones, T. H. // Internal Medicine Alert;5/29/2011 Supplement, p80 

    The article focuses on the study conducted by T. H. Jones regarding the effects of testosterone (TST) 2% gel daily applications in hypogonadal men with type 2 diabetes (DM2) and metabolic syndrome (MBS).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics